Tacrolimus (FK 506)—A New Therapeutic Agent for Severe Recalcitrant Psoriasis
نویسندگان
چکیده
منابع مشابه
FK 506: a new therapeutic agent for severe recalcitrant psoriasis.
BETWEEN 12 and 18 months ago we treated three patients with FK S06 who had severe psoriasis that was refractory to conventionai therapy and four patients with w,despread incidental psonasis before undergoing hean or liver transplantation under FK 506. All had dramatic resolution of psonasis. which remaIned in remission as long as full-dose therapy was provided. Serial skin biopsies had a rapid ...
متن کاملTacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.
BACKGROUND Psoriasis, a disease of unknown etiology, is in some patients severe, extremely debilitating, and unresponsive to conventional therapies, including UV-B, oral psoralen with long-wave UV radiation in the A range (PUVA), oral retinoids, and methotrexate. We report the results from our study of seven patients with refractory psoriasis who were treated with the new immunosuppressive drug...
متن کاملTopical Tacrolimus for Psoriasis
Tacrolimus ointment is an agent approved for the treatment of atopic dermatitis; however, tacrolimus has been expected also as one of the promising therapeutic strategies for other T-cell mediated inflammatory skin disorders. Recent progress have demonstrated that topical tacrolimus shows beneficial effects for psoriasis depending on sites. In particular, facial, intertriginous, and genital pso...
متن کاملAdalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
Tumor necrosis factor-α inhibitors may induce various cutaneous side effects including eczematous-like lesions. The management of such side effects can be challenging. Herein, we report a case of a 55-year-old man who had a flare-up and subsequent improvement of atopic dermatitis during treatment of severe psoriasis with adalimumab.
متن کاملCombination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis
Severe forms of psoriasis that are refractory to conventional therapies are often difficult to manage. The mammalian target of rapamycin (mTOR) inhibitors potentially have versatile effects toward putative psoriatic pathologic pathways. Therefore, mTOR inhibitors may offer a range of new therapeutic options for patients with psoriasis. We describe a 55-year-old male renal transplant patient wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Dermatology
سال: 1992
ISSN: 0003-987X
DOI: 10.1001/archderm.1992.01680160065005